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A B S T R A C T
Local delivery of compounds directly into the brain may become an attractive treatment option for
several neurological diseases. Higher therapeutic drug levelsmay be reached at the targeted brain region
and in this way systemic side effects avoided. This paper provides an overview of the currently
investigated experimental and clinical local delivery strategies in the brain ranging from delivery via
pump mechanisms to more advanced techniques with cell and gene therapy.
The second part focuses on local brain delivery strategies for epilepsy with special attention to
adenosine. Adenosine is a good candidate for local delivery techniques for epilepsy because of its proven
anticonvulsive effect and it cannot be given systemically because of systemic side effects. An overview of
the current published studies with local delivery of adenosine is given.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is one of themost prevalent neurological disorders and
generally requires lifetime treatment. For most patients antiepi-
leptic drugs (AEDs) are the mainstay of the management of
epilepsy.1 However in 30% of all epilepsy patients complete seizure
control cannot be achieved despite adequate treatment with AEDs
or patients may suffer from unacceptable systemic side effects.2
These patients with refractory epilepsy provide the impetus for a
continuous search for alternative treatment options.
One of the underlying causes of refractoriness may be
insufﬁcient bioavailability of the AED(s) at the ictal onset region.
Patients with refractory epilepsy are often resistant to a broad
range of AEDswith differentmechanisms of action, suggesting that
nonspeciﬁc mechanisms are responsible for their limited efﬁcacy.3
The entrance of drugs into the brain is limited by the blood brain
barrier (BBB). There is evidence that impaired drug penetration
into the brain may be due to (regional) overexpression of
(multi)drug efﬂux transporters at the site of the BBB.3–5 Those
transporters recognize a wide range of substrates, including
several AEDs.6 The prototype of these transporters is P-glycopro-* Corresponding author at: Department of Neurology, 1K12, 185, De Pintelaan,
9000 Ghent, Belgium. Tel.: +32 9 332 6946; fax: +32 9 332 4971.
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.03.003tein (P-gp). It is hypothesized that there is a constitutive or
inherited overexpression of P-gp as a result of a genetic
polymorphism7 or that overexpressionmay be acquired or induced
by some epilepsy-related factors such as uncontrolled seizures.8–10
In order to overcome the blood brain barrier – and circumvent-
ing multidrug transporters – local delivery of antiepileptic
substances directly into the epileptic focus is a tempting and
potentially promising strategy. This approach may reduce
systemic side effects and allows to deliver larger local doses to
obtain seizure control.11
This is an overview of the currently investigated strategies for
local delivery in the brain (Table 1) with special attention to local
brain delivery of adenosine for the treatment of epilepsy.
2. Strategies for local compound delivery in the brain
2.1. Intraventricular or intrathecal administration
The BBB can be bypassed by administration of drugs directly
into the cerebrospinal ﬂuid (CSF) via compound infusion through
intraventricular of intrathecal catheters. Despite the fact that 100%
of the administered drug reaches the brain, this administration
route has several disadvantages. One major limitation is the non-
uniformdrug distribution throughout the subarachnoid spacewith
very high local concentrations at the administration site and very
low to zero concentrations at a distance.11,12 Penetration from thevier Ltd. All rights reserved.
Table 1
Current local delivery strategies in the brain.
Non-biological source Biological source
Intraventricular or intrathecal administration
through catheters or via minipumps
Cell transplants
Polymeric controlled release (‘wafers’) Gene therapy
Convection-enhanced delivery (CED)
Carrier vehicles: nanoscaled particles
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weight compounds, but may be enhanced by creating a pressure
gradient (‘convection’, see further).13
When a drug is injected into the cerebral ventricle, the
elimination rate from the central nervous system is dependent
on the cerebrospinal ﬂuid dynamics.12 Injection volume, osmolar-
ity, pH, injection rate, etc. may inﬂuence this balance and have an
impact on efﬁcacy and safety of this administration route.14 Other
pitfalls with this delivery strategy are difﬁculties in maintaining
access (e.g. catheter problems) and possible neurotoxicity.11,15
Direct drug delivery into the CSF is performed in the oncology
domain as a form of regional chemotherapy.11 Themost commonly
used application consists of continuous intrathecal infusion of
baclofen or narcotics via a subcutaneous implanted pump for
management of spasticity and pain. Although much experience is
available with this technique, there are still possible complications
mostly related to pump or catheter malfunction.16,17
2.2. Polymeric controlled release (‘wafers’)
Biocompatible synthetic polymers, impregnated with a speciﬁc
compound, may be used as a source for controlled drug release in
the brain. Biodegradable polymers release the compound while
breaking down, whereas the matrix of non-degradable polymers
remains intact after complete release of the drug. Of course the
need for removal of the non-degradable polymers limits their use
for clinical applications in the brain. The polymers itself are made
from various materials and the complex of the polymer and the
drug is mostly referred to as a ‘wafer’.18 The pharmacokinetics
depend on the polymer and the characteristics of the released
compound. Biodegradable polymer wafers with controlled release
of carmustine (‘Gliadel1’ wafers) are approved for clinical use for
the treatment of high-grade gliomas.19 Since the successful
development of this wafer, other chemotherapeutic agents are
also used or investigated for incorporation into polymers.20
2.3. Convection-enhanced delivery (CED)
Poor penetration into the brain and limitation of drug dosage at
the implant site are disadvantages of the intraventricular/
intrathecal administration and implantation of compound-
releasing wafers as described above. To overcome these problems,
the technique of ‘convection-enhanced delivery’ (CED) has been
developed.13 CED is deﬁned as the infusion of a therapeutic ﬂuid
via surgically implanted catheters under positive pressure. By
using a syringe pump, continuous positive pressure creates a bulk
ﬂow mechanism (i.e. convection). Compared to diffusion alone, a
greater distribution volume is achieved.21,22 The precise area
reached using CED depends on different factors like infusion rate,
infusion volume, cannula size and compound characteristics.
Especially catheter-related problems with air bubbles and
backﬂow of the solution may interfere with the distribution area
and are a challenge for the neurosurgeon.23 It is not an approved
treatment yet, but clinical trials with administration of che-
motherapeutics to treat brain tumours using CED have been
performed. Nanoscaled particles can also be administered via CEDto obtain deep penetration of the nanoparticles into the brain
parenchyma.21
2.4. Carrier vehicles: nanoscaled drug delivery systems
This strategy for drug delivery in the brain makes use of very
small (‘nano-scaled’) carriers which can be administered orally,
pass the BBB and release the compound into the brain.
Nanoparticles are by deﬁnition smaller than 100 nm, but for
medical purposes also larger particles (up to 1000 nm) are used.
Because of their small size, they can penetrate cell membranes,
including the BBB, and may be an ideal source for local drug
delivery. The active compound can be adsorbed on the surface,
enclosed in the shell or trapped inside its core.24
Major advantages of this strategy are the improvement of
solubility of poorly water-soluble drugs, increase of the half-life of
drug systemic circulation with a constant rate of drug delivery at
the target zone and the reduction of systemic side effects by
delivering at the target place.25,26
Although the use of nanoparticles seems a promising strategy,
there are deﬁnitely some limitations. First, due to their physical
properties there is rapid clearance of colloidal nanoparticles from
the blood stream and accumulation in the liver or spleen. This may
be partially solved by addition of polyethylene glycol to the
surface. A second pitfall is toxicity of some nanoscaled drug
delivery systems, especially in case of non-degradable particles.27
More research on the long-term safety of nanoparticles is
warranted. Meanwhile some nano-particle based therapies are
in the stage of clinical trials, but not targeted to the brain. Studies
for brain-delivery are still in the experimental phase.26
2.5. Cell transplants
Biological substances can be delivered locally in the brain via
transplanted cells. In the ﬁrst experimental and clinical studies,
fetal cells were grafted for cell-based delivery of therapeutic
compounds. Since the use of fetal cells implies many practical and
ethical problems, a lot of research is done to develop a strategy
where stem cells are used as a source for local delivery in the
brain.28–31 Stem cells are pluripotent cells with the ability to divide
and renew themselves for indeﬁnite periods (‘long-term self-
renewal’) and to develop – under the right physiological or
experimental conditions – into mature specialized cells, e.g. nerve
cells.32 Different types of stem cells are currently used experimen-
tally for transplantation into the brain: embryonic stem (ES) cells,
(adult) neural stem cells or induced pluripotent stem cells.28,30
The basic principles for cell transplantation are identical for the
different cell sources. Stem cells are isolated, followed by in vitro
expansion. If necessary – especially in case of embryonic stem cells
– predifferentiation and/or genetic modiﬁcation may be per-
formed. Stem cells can be engineered to secrete neurotransmitters,
neuromodulators or neuropeptides, making them an attractive
tool in the treatment of different neurological disorders. Next, stem
cells are transplanted in the host where they should survive and
provide clinical beneﬁts by local delivery of a therapeutic
compound.30,33,34
The overall advantage of using cells for compound delivery is
the lack of necessity to reﬁll or replace pumps, polymers or carrier
vehicles. A major disadvantage with cell grafting is the lack of
control and the fact that only biological compounds can be
delivered with this approach.
2.6. Gene therapy
Gene therapy is deﬁned as ‘the transfer of therapeutic genetic
material into cells as a mean to rectify disease’.35 Using gene
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to treat neurological disorders. Gene therapymay be performed ‘ex
vivo’: genetic transfer to cultured cells prior to transplantation, or
‘in vivo’: direct transfer of genetic material into cells in vivo using
viral and chemical agents.29,36 The most efﬁcient way to introduce
or replace a speciﬁc gene in a cell consists of using a viral vector of
which the pathogenic genes are deleted. The most commonly used
viral vectors are retroviruses (with the subclass of lentiviruses),
adeno-associated viruses (AAV) and herpes simplex viruses.37–39 In
case of ‘ex vivo’ gene therapy ES cells or neural stem cells are
frequently used because they can be expanded to large amounts of
cells and differentiated to various types of neural cells. The main
advantage of ‘ex vivo’ gene therapy is the possibility to enrich the
cells for a speciﬁc phenotype and screen for transduction-induced
defects prior to transplantation. The disadvantage of ‘ex vivo’ gene
therapy is the limited capacity of stem cells to integrate into the
brain and to generate speciﬁc neural phenotypes.
‘In vivo’ gene therapy targets endogenous neural cells into the
region of interest. ‘In vivo’ gene therapy overcomes the problems
associated with cell transplantation but is associated with a risk of
transduction-induced mutagenesis and unspeciﬁc transduction of
several neural phenotypes.35
3. Local delivery strategies for epilepsy with adenosine
Since epilepsy is a chronic disorder, lifelong treatment may be
indicated and chronic local delivery is needed. Use of local delivery
therapies with polymers or carrier vehicles are useful for short-
time delivery, e.g. chemotherapeutics for brain tumours, but in
epilepsy the most successful strategies may be based on cell or
gene therapy, since they do not require replacement or reﬁlling
and long-term release is theoretically possible.
Different chronic local delivery strategies have been investigat-
ed with various antiepileptic compounds: antiepileptic drugs like
valproic acid,40 phenobarbital and gabapentin,41 the purine
ribonucleoside adenosine,42–51 the neurotransmitters acetylcho-
line,52 GABA,53–62 norepinephrine63–69 and serotonin,70 and the
neuropeptides galanine71–73 and neuropeptide Y.74–77 Here we
focus on local delivery strategies with adenosine based on
promising preclinical results.
First, somemajor characteristics of adenosinewill be described.
Then, an overview of preclinical studies on local delivery of
adenosine will be presented (see also in Table 2).Table 2
Overview of the studies performed with local delivery of adenosine. Of each study, the so
The disadvantages of the several strategies are highlighted. The restriction of the use of p
use of transplantation of adenosine-releasing cells directly into the brain. However th
transplantation. Also long-term effects of cell-based strategies are not known (Ref. = re
Local delivery technique Adenosine releasing source Implantati
Polymer Synthetic ethylene vinyl acetate copolymer Lateral ven
Silk-based polymer Infrahippo
ﬁssure
Pump Osmotic minipumps Hippocam
Cell-based therapy Encapsulated baby hamster kidney cells Lateral ven
Encapsulated mouse myoblasts Lateral ven
Encapsulated mouse embryonic stem cells Lateral ven
Neural precursor cells derived from
embryonic stem cells
Hippocam
Human mesenchymal stem cells Infrahippo
ﬁssure
Fetal neural progenitor cells Not yet pe
Gene therapy Not yet performed in vivo3.1. Adenosine: physiology and its role in epilepsy
Adenosine is a purine ribonucleoside and plays an important
role in many physiological processes, e.g. sleep induction,
regulation of the heart rate and blood pressure, regulation of pain
perception, neuroprotection and seizure susceptibility.78 It is an
endogenous neuromodulator present in the intra- and extracellu-
lar environment of the brain. Adenosine is mainly formed by the
breakdown of intra- and extracellular adenine nucleotides via
nucleotidases (Fig. 1). Alternatively adenosine can be produced via
hydrolysis of S-adenosyl homocysteine (SAH), but this is an
uncommon pathway in the brain.
Under normal physiological conditions, the amounts of adeno-
sine in cells and tissue ﬂuids are in the nanomolar range, but in
situations of cellular distress – e.g. ischemia or seizures –
adenosine levels rapidly increase. Intracellular adenosine triphos-
phate (ATP)-levels are high (several millimolars) and in case of cell
damage ATP is released into the extracellular environment and
rapidly transformed to adenosine by ectonucleotidases. The
intracellular formation of adenosine increases with increased
cellular workload and is related to increased oxygen consump-
tion.79,80 The intra- and extracellular adenosine concentrations
equilibrate via passive nucleoside transporters.
Adenosine is catabolized by adenosine deaminase (ADA) and
adenosine kinase (ADK). Especially ADK, that is mainly present in
astrocytes in the brain, is important to maintain the levels of
adenosine constant and low.80
Adenosine acts via binding to speciﬁc G-protein coupled
adenosine receptors: the A1, A2A, A2B and A3 receptors.
81
Throughout the nervous system, there is a speciﬁc distribution
of these receptors. The A1 and A2A receptors are most abundant in
the brain and are responsible for the majority of the physiological
effects.82 The inhibitory effect of adenosine is mediated by binding
to the high-afﬁnity A1 receptor present in the cerebral cortex,
hippocampus, thalamus, cerebellum, brain stem and the spinal
cord. This receptor is coupled to an inhibitory G protein (Gi) leading
to inhibition of adenylyl cyclase, activation of phospholipase C,
increase of conductance of K+ channels and inhibition of
presynaptic Ca2+ channels. Activation of presynaptic A1 receptors
results in inhibition of release of excitatory neurotransmitters
(glutamate) whereas activation of the postsynaptic A1 receptors
hyperpolarizes neurons.82,83 These inhibitory effects play an
important role in epilepsy. During an epileptic seizure, extracellu-}
}
}
urce of adenosine release, the implantation site and the animal model is mentioned.
olymers or pumps is the need for reﬁlling or replacement. This may be solved by the
is is coupled with limited control on cell integration and adenosine release after
ference).
on site Animal model Disadvantage Ref.
tricle Kindling model
Effect limited to adenosine
volume in polymer or pump
42
campal Kindling model 49
51
pus Intraperitoneal
kainic acid model
50
tricle Kindling model Limited effect because of limited
cell survival
45
tricle Kindling model 44
tricle Kindling model 43
pus Kindling model
Limited control on cell integration
and adenosine release after
transplantation
Long-term effects not known
46
campal Model for CA3-selective
epileptogenesis
Intrahippocampal kainic
acid model
47
48
rformed 99
100
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Fig. 1. Left: chemical structure of adenosine. Right: metabolism of adenosine: adenosine is present in the intra- (IC) and extracellular (EC) environment in the brain. It is
mainly formed by the breakdown of intra- and extracellular adenine nucleotides (ATP/ADP/AMP) via nucleotidases (NT). Formation of adenosine out of S-
adenosylhomocysteine (SAH) via hydrolysis of S-adenosyl homocysteine (SAHH) is an uncommon pathway in the brain. Adenosine is catabolised by adenosine deaminase
(ADA) to inosine (Ino) and by adenosine kinase (ADK) to AMP. The intra- and extracellular adenosine concentrations equilibrate via equilibrative nucleoside transporters
(ENT).
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role in the termination of the seizure via binding to the inhibitory
A1 receptor. During the progression of epilepsy, an increase in ADK
levels is observed, in parallel with ongoing astrogliosis often found
in epilepsy. Increase of ADK leads to lower ambient levels of
adenosine which may contribute to refractory epilepsy.84 There-
fore adenosine administration may be a potential treatment for
epilepsy. Since it cannot be given systemically because of its severe
side effects such as decreased heart rate, blood pressure and body
temperature, local delivery of adenosine may be a promising
alternative.84
3.2. Strategies for local delivery of adenosine in epilepsy
Initial studies with acute administration of adenosine (analo-
gues) into the brain of epileptic animals have proven the seizure
suppressive effects of adenosine.85–89 As a next step, adenosine
was infused chronically in the kindling model and the post-status
epilepticus model for temporal lobe epilepsy. In the kindling
model, seizures are provoked by repeated administration of short
electrical stimuli in limbic brain regions (hippocampus, amygdala).
The provoked seizure is visible as the ‘afterdischarge’: a high
amplitude, high frequency discharge on the EEG. The ‘seizure
severity’ refers to the clinical manifestation of the seizure and is
scored according to the 5 stages of Racine: stage 1, immobility, eye
closure, twitching of vibrissae, facial clonus, wet dog shakes; stage
2: head nodding, chewing, severe facial clonus, wet dog shakes;
stage 3: clonus of one forelimb; stage 4: rearing, bilateral forelimb
clonus; stage 5: rearing, bilateral forelimb clonus, loss of balance
and falling.90 Seizure severity and afterdischarge duration are
important parameters to evaluate therapeutic effect of an
experimental treatment in the kindling model.91,92
Post-status epilepticus (SE) models are characterized by
spontaneous seizures. In these models a SE is evoked by tetanic
electrical stimulation of the brain or administration of a
chemoconvulsant (kainic acid, pilocarpine).93 After a latent period,
the spontaneous seizures develop typically concomitant with
histopathological changes in the hippocampus as seen in patients
with refractory temporal lobe epilepsy. These post-SE animal
models are considered to resemble more the human epilepsy
condition than the kindling model.94The ﬁrst study describing chronic delivery of adenosine in the
brain was performed by Boison et al. In this experiment, adenosine
was delivered into the lateral ventricle via a synthetic ethylene vinyl
acetate copolymer.42 In vitro the polymers released approximately
20–50 ng adenosine per day. Individual polymers were implanted
into the lateral brain ventricles of kindled rats. As long as
adenosine was released by the polymers (i.e. 14 days), a sustained
reduction of stimulus-induced seizures was found.
Recently, an alternative synthetic drug delivery system based
on silk ﬁbroin was developed.51 The use of silk ﬁbroin has several
advantages because it is biocompatible and biodegrades slowly,
allowing an increased release time.95 The adenosine releasing silk-
based polymerswas implanted into the infrahippocampal ﬁssure of
fully kindled rats and naı¨ve rats prior to kindling. These
experiments showed a dose-dependent suppression of kindled
seizures and a decrease of the kindling rate. The polymers released
adenosine for 10 days and this corresponded nicelywith the period
of seizure suppression.49,51
Van Dycke et al. administered adenosine via osmotic minipumps
directly into the hippocampi of rats with spontaneous seizures.
Continuous delivery of high doses of adenosine (33mg per day)
resulted in a mean reduction of (both convulsive and non-
convulsive) seizures of 33% compared to the baseline seizure
frequency without side effects.50 In saline-treated control rats
seizure frequency further increased with 35% compared to the
baseline. The therapeutic effect was completely reversed after
stopping local delivery of adenosine.
Although results of polymer and pump-based delivery are
promising, the disadvantage of these systems is the loss of seizure
control after complete compound release. In order to obtain more
sustained adenosine release and seizure suppression, cell-based
therapies for adenosine were developed. Kidney ﬁbroblasts,45
mouse myoblasts44 and mouse embryonic stem cells43,96 were
genetically engineered in order to release adenosine by disrupting
the gene for ADK through chemicalmutagenesis or via homologous
recombination. Due to the absence of ADK expression, less
adenosine is phosphorylated to adenosine monophosphate
(AMP) resulting in an intracellular accumulation of adenosine.
As a result adenosine is passively secreted by the genetically
engineered adenosine kinase knockout (Adk/) cells via the
nucleoside transporters (Fig. 1).
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adenosine per 100,000 cells per 24 h in culture. After encapsulation
of adenosine releasing cells in a semi-permeable membrane, capsules
were transplanted in the lateral ventricles of fully kindled rats.43–45
Transplantation of engineered kidney ﬁbroblasts and myoblasts
resulted in an almost complete suppression of kindled seizures up
to 14 days after transplantation in fully kindled rats. After 14 days a
gradual loss of seizure control was found because of the limited
survival of the encapsulated cells. This survival-dependent effect
was also obvious in experiments where mouse embryonic stem
cell derived glial cells were transplanted into fully kindled rats.
Three days after transplantation 90% of the transplanted cells were
still present in the host brain with complete seizure suppression in
100% of the animals. Seven days after transplantation however,
seizure suppression was lost and viable cells were no longer
detectable. In all these studies, seizure suppressing effects were
conﬁrmed to be mediated by the paracrine release of adenosine
since injection of the A1 receptor antagonist DPCPX (8-cyclopentyl-
1,3-dipropyl-xanthine) abolished the adenosine-induced seizure
suppressing effects.
Probably because the adenosine releasing cells were encapsu-
lated in these experiments, survival of the cells – and thus the
antiseizure effect – was limited. Transplantation of cells into the
brain parenchymamay increase cell survival and adenosine release
resulting in prolonged antiseizure effects.97
Adenosine-releasing embryonic stem cells, predifferentiated
towards neural precursor cells prior to transplantation, were
grafted intrahippocampally prior to hippocampal kindling.46 A
fraction of the cells survived at least four weeks after transplanta-
tion and expressed markers of mature neurons at that time point.
Transplantation of adenosine-releasing neural precursor cells
induced a decrease of the kindling rate.
In a following experiment, use of a lentiviral system resulted in
an up to 80% downregulation of ADK expression in human
mesenchymal stem cells (hMSCs), resulting in sustained secretion
of adenosine by the hMSCs.48 Transplantation of these engineered
hMSCs in the infrahippocampal ﬁssure of mice suppressed seizure
activity and neuronal damage during SE.48 When these hMSCs
were transplanted in the same region one day after the SE, mice
developed less spontaneous seizures three weeks after transplan-
tation compared to mice implanted with control cells.47
Van Dycke et al. isolated Adk/ neural stem cells from
adenosine kinase knockout mice as an alternative potential cell
source for local delivery of adenosine. Since Adk/mice die within
14 days due to hepatic steatosis, the isolation of adult neural Adk/
 stem cells was not a possibility.98 Therefore Adk/ neural stem
cells were isolated from fetuses at embryonic day 14. The amount
of adenosine release in stem cell culture medium (i.e. in vitro) was
evaluated together with their differentiation potential.99,100 We
found that, compared with data from the above described studies,
the amount of secreted adenosine – both from non-differentiated
and differentiated fetal Adk/ cells – was sufﬁcient to obtain a
therapeutic effect in the treatment of refractory epilepsy.
Local delivery via stem/progenitor cell transplantation may
become an option to treat refractory patients with epilepsy but
further research is needed on long-term results in models with
spontaneous seizures. Cells must survive and the secretion of the
antiepileptic compound must be stable. It has been demonstrated
that the survival rate of grafted cells is inversely correlated with
the delay between the kainic acid induced status epilepticus and
the transplantation.101–103 However there are several ways to
enhance cell survival after transplantation, e.g. via supplementa-
tion of anti-apoptotic or neurotrophic factors.104 To monitor in
vivo secretion of adenosine after transplantation, in vivo monitor-
ing methods are currently developed for adenosine and other
neurotransmitters.105Studies with (in vivo) gene therapy have not been performed for
adenosine yet, but is could be an interesting option considering the
successful studies with gene therapy for galanine71–73 and
neuropeptide Y.75,77
4. Conclusion
Local delivery strategies are an attractive option for treating
neurological diseases since systemic side effects may be dimin-
ished and higher therapeutic doses may reach the brain. In
epilepsy, several studies have shown the antiseizure effect of local
adenosine delivery. Local delivery using polymers and pumps are
controllable sources, but have the disadvantage of the need for
reﬁlling or replacement. Transplantation of adenosine releasing
stem/neural progenitor cells can resolve this problem since long-
term integration and secretion of adenosine is possible. The pitfall
with this strategy is the limited control on cell integration and
adenosine release after transplantation. Further studies with
evaluation of long-term effects of cell-based therapies are
warranted. Furthermore in vivo gene therapy may also be an
attractive strategy, but has not been tested in case of adenosine.
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